NCT05626400 2022-11-25
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Recruiting
Hebei Senlang Biotechnology Inc., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.